VEGF gene polymorphisms and as a potential roles of bladder cancer recurrence factor

The study explores how certain variations in the VEGF (vascular endothelial growth factor) gene may influence the recurrence of bladder cancer, shedding light on its development and prognosis. Bladder cancer, mainly urothelial carcinoma, is complex and unpredictable, posing challenges for treatment. Understanding genetic factors, like VEGF gene variations, can help tailor treatment plans for better outcomes. The study highlights various pathways involved in bladder cancer progression, including the role of VEGF beyond just blood vessel growth. While some research suggests a connection between VEGF gene variations and bladder cancer risk, results vary. Identifying thesevariations could lead to personalized treatments and targeted therapies. However, more research is needed to understand how these genetic factors specifically affect cancer recurrence. Collaborative efforts and advanced studies are essential for improving bladder cancer management and patient outcomes.